OA10716A - Ligands for flt3 receptors - Google Patents

Ligands for flt3 receptors Download PDF

Info

Publication number
OA10716A
OA10716A OA60744A OA60744A OA10716A OA 10716 A OA10716 A OA 10716A OA 60744 A OA60744 A OA 60744A OA 60744 A OA60744 A OA 60744A OA 10716 A OA10716 A OA 10716A
Authority
OA
OAPI
Prior art keywords
flt3
cells
polypeptide
csf
patient
Prior art date
Application number
OA60744A
Other languages
English (en)
Inventor
Stewart D Lyman
Patricia M Beckmann
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of OA10716A publication Critical patent/OA10716A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
OA60744A 1993-05-24 1995-11-21 Ligands for flt3 receptors OA10716A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6839493A 1993-05-24 1993-05-24
US10646393A 1993-08-12 1993-08-12
US11175893A 1993-08-25 1993-08-25
US16240793A 1993-12-03 1993-12-03
US20950294A 1994-03-07 1994-03-07

Publications (1)

Publication Number Publication Date
OA10716A true OA10716A (en) 2002-12-09

Family

ID=27535798

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60744A OA10716A (en) 1993-05-24 1995-11-21 Ligands for flt3 receptors

Country Status (16)

Country Link
US (3) US5554512A (sv)
JP (1) JP4028594B2 (sv)
KR (1) KR100319359B1 (sv)
CN (1) CN1123574C (sv)
AU (1) AU683472B2 (sv)
BR (1) BR9407073A (sv)
CA (1) CA2162397C (sv)
FI (1) FI955646A (sv)
HU (1) HUT74831A (sv)
MY (1) MY148148A (sv)
NO (1) NO322373B1 (sv)
NZ (1) NZ267541A (sv)
OA (1) OA10716A (sv)
PL (1) PL311756A1 (sv)
UA (1) UA42726C2 (sv)
WO (1) WO1994028391A1 (sv)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537932B1 (en) 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
EP0992584A3 (en) * 1993-05-19 2000-06-07 Schering Corporation Purified mammalian FLT3 ligands and agonists and antagonists thereof
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
US5789655A (en) * 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
JPH11509845A (ja) * 1995-07-21 1999-08-31 アメリカ合衆国 造血多分化性細胞移植のための放射線または放射線類似作用化学療法の減少方法
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
EA199800272A1 (ru) 1995-10-04 1998-10-29 Иммунекс Корпорейшн Фактор, стимулирующий дендритные клетки
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US20030103988A1 (en) * 1995-10-26 2003-06-05 Leonard Chess Regulation of activated t cells by recognition of t cell receptor beta chains and major histocompatibility complex class ib molecules
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
WO1998057655A1 (en) * 1997-06-17 1998-12-23 Immunex Corporation A method of enhancing antigen-specific peripheral immune tolerance
AU1705599A (en) * 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
AU2333999A (en) * 1998-01-23 1999-08-09 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
US6649352B1 (en) * 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
AU777963B2 (en) * 1999-05-19 2004-11-04 Merck Patent Gmbh Expression and export of interferon-alpha proteins as Fc fusion proteins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
CA2394015C (en) 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1294401B1 (en) 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
JP4394350B2 (ja) 2001-01-09 2010-01-06 ベイラー リサーチ インスティテュート 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
JP4309662B2 (ja) 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
US20030017529A1 (en) * 2001-06-27 2003-01-23 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US7070996B2 (en) * 2001-08-31 2006-07-04 Rigel Pharmaceuticals, Inc. Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
US20030124091A1 (en) * 2001-10-26 2003-07-03 Large Scale Biology Corporation Endothelial cell derived hematopoietic growth factor
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2003083083A2 (en) * 2002-03-26 2003-10-09 Immunex Corporation Methods of using flt3-ligand in immunization protocols
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
EP1633398A4 (en) * 2003-06-13 2007-02-28 Oncomax Acquisition Corp PREPARATION AND APPLICATION OF BIFUNCTIONAL ANTI-TUMOR HYBRID PROTEINS
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
AU2004299457B2 (en) 2003-12-12 2011-03-24 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
JP2007516984A (ja) * 2003-12-24 2007-06-28 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 治療用物質およびそのための用途
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
JP4987484B2 (ja) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 補体結合が低下した抗癌抗体
CN100404683C (zh) * 2004-05-27 2008-07-23 中国医学科学院基础医学研究所 一种人fl多核苷酸及其与人gm-csf联合基因治疗恶性肿瘤的用途
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008505650A (ja) * 2004-07-12 2008-02-28 ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ ヒト細胞を増殖させるための装置及び方法
EP1786474B1 (en) * 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
EP1860180A4 (en) * 2005-02-23 2009-03-11 Found Biomedical Res & Innov METHOD FOR IN VITRO AMPLIFICATION OF ENDOTHELIAL PROGENITOR CELL
US20090050204A1 (en) * 2007-08-03 2009-02-26 Illuminex Corporation. Photovoltaic device using nanostructured material
US20070048254A1 (en) * 2005-08-24 2007-03-01 Mirus Bio Corporation Generation of dendritic cells
US7482165B2 (en) * 2005-08-24 2009-01-27 Beckman Coulter, Inc. Method of preventing white blood cell interferences to red blood cell measurements of a blood sample
DK1966245T3 (da) 2005-12-30 2011-07-18 Merck Patent Gmbh Anti-CD19-Antistoffer med reduceret immunogenicitet
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
EP1991547A2 (en) * 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US8883493B2 (en) * 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US8834409B2 (en) 2008-07-29 2014-09-16 Covidien Lp Method for ablation volume determination and geometric reconstruction
CA2681236A1 (en) * 2008-10-24 2010-04-24 Mount Sinai School Of Medicine Of New York University Methods and compositions for treatment of fibrosis
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
CN102458458B (zh) 2009-04-17 2016-11-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
RU2635317C2 (ru) * 2009-10-19 2017-11-10 Тристем Трейдинг (Сайпрес) Лимитед Лечение с применением перепрограммированных зрелых и дифференцированных клеток
AU2010333322B2 (en) * 2009-12-18 2016-02-04 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells and uses thereof
WO2012019160A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
WO2012065755A1 (en) 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN103827292B (zh) 2011-07-01 2018-01-26 安姆根有限公司 哺乳动物细胞培养
CA2840637A1 (en) 2011-09-02 2013-03-07 Amgen Inc. Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
SG11201406141UA (en) * 2012-03-28 2014-10-30 Quarrymen Corp Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
EP3063287A1 (en) 2013-10-31 2016-09-07 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
EP3094735A1 (en) 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
PL3152317T3 (pl) 2014-06-04 2019-08-30 Amgen Inc. Sposoby zbierania hodowli ssaczych komórek
US11275090B2 (en) 2014-11-19 2022-03-15 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2017218638A1 (en) * 2016-06-14 2017-12-21 Jianjun Chen Methods for treating subjects suffering from acute myeloid leukemia with flt3 ligand-targeted mir-150 nanoparticles
AU2017294751B2 (en) 2016-07-13 2023-10-05 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
WO2019147982A1 (en) 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
CN111989117A (zh) * 2018-02-14 2020-11-24 维埃拉生物股份有限公司 麦克唐纳猫肉瘤(fms)样酪氨酸激酶3受体配体(flt3l)的抗体及其用于治疗自身免疫性疾病和炎性疾病的用途
CA3099163A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Antibodies with modulated glycan profiles
AU2019359890A1 (en) 2018-10-17 2021-06-03 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020198661A1 (en) * 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
CA3136626A1 (en) * 2019-04-12 2020-10-15 Emory University Compositions and methods for promoting hematopoietic cell cytotoxicity
KR20220032568A (ko) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
US20230398184A1 (en) * 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5057420A (en) * 1987-06-05 1991-10-15 Granada Biosciences, Inc. Bovine nuclear transplantation
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
JPH0611705B2 (ja) * 1988-02-10 1994-02-16 新技術事業団 血小板減少症治療剤
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5763266A (en) * 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
WO1992018615A1 (en) * 1991-04-09 1992-10-29 Indiana University Foundation System and process for supporting hematopoietic cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE69232682T2 (de) * 1991-10-23 2003-03-13 Nexell Therapeutics Inc., Irvine Verfahren zur selektiven vermehrung von cd34 positiven zellen
AU2882992A (en) * 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand

Also Published As

Publication number Publication date
HUT74831A (en) 1997-02-28
MY148148A (en) 2013-03-15
NZ267541A (en) 1997-06-24
NO954735L (no) 1996-01-23
US5843423A (en) 1998-12-01
AU6987794A (en) 1994-12-20
WO1994028391A1 (en) 1994-12-08
PL311756A1 (en) 1996-03-18
BR9407073A (pt) 1996-08-27
CN1125479A (zh) 1996-06-26
US5554512A (en) 1996-09-10
CA2162397A1 (en) 1994-12-08
US20030148516A1 (en) 2003-08-07
UA42726C2 (uk) 2001-11-15
KR100319359B1 (ko) 2002-07-31
JP4028594B2 (ja) 2007-12-26
CA2162397C (en) 2007-04-03
AU683472B2 (en) 1997-11-13
JPH08511251A (ja) 1996-11-26
NO322373B1 (no) 2006-09-25
CN1123574C (zh) 2003-10-08
FI955646A (sv) 1996-01-23
HU9503341D0 (en) 1996-01-29
NO954735D0 (no) 1995-11-23
US6919206B2 (en) 2005-07-19
FI955646A0 (sv) 1995-11-23

Similar Documents

Publication Publication Date Title
US5843423A (en) Methods of stimulating hematopoietic cells with flt3-ligand
US7041282B2 (en) Ligands for flt3 receptors
US20110053863A1 (en) Methods of using flt3-ligand in the treatment of cancer
US6190655B1 (en) Methods of using Flt-3 ligand for exogenous gene transfer
US7045128B2 (en) Antibodies against flt3-ligand
US6630143B1 (en) Antibodies against flt3 ligand
US20140099710A1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
JP4224624B2 (ja) 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ
JP4251983B2 (ja) 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ
US20090131634A1 (en) Method for Preparing Cell Fraction Containing Hemangioblasts
Takatsu et al. Interleukin 5 and its receptor
RU2220979C2 (ru) ПОЛИПЕПТИД ЛИГАНДА flt3 (ВАРИАНТЫ), ПОЛИНУКЛЕОТИД(ВАРИАНТЫ), ЭКСПРЕССИРУЮЩИЙ ВЕКТОР(ВАРИАНТЫ), ЛИНИЯ КЛЕТОК СНО (ВАРИАНТЫ), СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА ЛИГАНДА flt3 (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ)
MXPA94003806A (en) Ligands for receivers f
US20050059145A1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
Friend Identification of a novel growth factor and the role of thymic stroma in hematopoiesis
He The role of the common gamma-c subunit of IL-2, IL-4, IL-7, IL-9, and IL-15 receptors in ligand-receptor interactions and lymphocyte development
IMHOF¹ et al. 6. THE ONTOGENY OF LYMPHOCYTES AND HOMING TO THE THYMUS